Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: Single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib

Leukemia

Volumn 28, Issue 6, 2014, Pages 1363-1365

  Lasho, T L ^a   Mims, A ^b   Elliott, M A ^a   Finke, C ^a   Pardanani, A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; COLONY STIMULATING FACTOR 3 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; RUXOLITINIB; SET BINDING PROTEIN 1; UNCLASSIFIED DRUG; FEDRATINIB; SETBP1 PROTEIN;

AGED; BONE MARROW CELL; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CASE REPORT; CELL SURFACE; CHRONIC NEUTROPHILIC LEUKEMIA; CLONAL VARIATION; CYTOGENETICS; DNA SEQUENCE; DRUG DOSE INCREASE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; GRANULOCYTE; HUMAN; IN VITRO STUDY; LETTER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; THROMBOCYTE COUNT; TREATMENT RESPONSE; ADD ON THERAPY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; LEUKOCYTE COUNT; MONONUCLEAR CELL; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARRIER PROTEINS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ERYTHROID CELLS; FEMALE; GRANULOCYTES; HUMANS; HYDROXYUREA; JANUS KINASE 2; LEUKEMIA, NEUTROPHILIC, CHRONIC; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PYRAZOLES; RECEPTORS, COLONY-STIMULATING FACTOR; TUMOR CELLS, CULTURED;

EID: 84902080313     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.39     Document Type: Letter

References (8)

1. Germeshausen M, Welte K, Ballmaier M. In vivo expansion of cells expressing acquired CSF3R mutations in patients with severe congenital neutropenia. Blood 2009; 113: 668-670.
2. Kunter G, Woloszynek JR, Link DC. A truncation mutant of Csf3r cooperates with PML-RARalpha to induce acute myeloid leukemia in mice. Exp Hematol 2011; 39: 1136-1143.
3. Beekman R, Valkhof MG, Sanders MA, van Strien PM, Haanstra JR, Broeders L et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 2012; 119: 5071-5077.
4. Plo I, Zhang Y, Le Couedic JP, Nakatake M, Boulet JM, Itaya M et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med 2009; 206: 1701-1707.
5. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368: 1781-1790.
6. Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood 2013; 122: 3628-3631.
7. Kosmider O, Itzykson R, Chesnais V, Lasho T, Laborde R, Knudson R et al. Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia 2013; 27: 1946-1949.
8. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27: 1870-1873.